PD-1 inhibitors in patients with Hodgkin lymphoma

Eur J Cancer. 2022 Mar:164:114-116. doi: 10.1016/j.ejca.2021.06.059. Epub 2021 Aug 26.

Authors

Cédric Rossi¹, René-Olivier Casasnovas²

Affiliations

¹ Department of Hematology, CHU Dijon-Bourgogne, Hôpital François Mitterrand, Dijon, France; INSERM, 1231 Unit, UFR Bourgogne Franche-Comté, France. Electronic address: cedric.rossi66@gmail.com.
² Department of Hematology, CHU Dijon-Bourgogne, Hôpital François Mitterrand, Dijon, France; INSERM, 1231 Unit, UFR Bourgogne Franche-Comté, France.

PMID: 34456113
DOI: 10.1016/j.ejca.2021.06.059

No abstract available

Publication types

Editorial

MeSH terms

B7-H1 Antigen
Hodgkin Disease* / drug therapy
Hodgkin Disease* / pathology
Humans
Immune Checkpoint Inhibitors*
Programmed Cell Death 1 Receptor / therapeutic use

Substances

B7-H1 Antigen
Immune Checkpoint Inhibitors
Programmed Cell Death 1 Receptor